JP2017514867A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514867A5
JP2017514867A5 JP2016566786A JP2016566786A JP2017514867A5 JP 2017514867 A5 JP2017514867 A5 JP 2017514867A5 JP 2016566786 A JP2016566786 A JP 2016566786A JP 2016566786 A JP2016566786 A JP 2016566786A JP 2017514867 A5 JP2017514867 A5 JP 2017514867A5
Authority
JP
Japan
Prior art keywords
group
alkyl
optionally substituted
heterocyclyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016566786A
Other languages
English (en)
Japanese (ja)
Other versions
JP6479854B2 (ja
JP2017514867A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/059453 external-priority patent/WO2015169677A1/en
Publication of JP2017514867A publication Critical patent/JP2017514867A/ja
Publication of JP2017514867A5 publication Critical patent/JP2017514867A5/ja
Application granted granted Critical
Publication of JP6479854B2 publication Critical patent/JP6479854B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016566786A 2014-05-07 2015-04-30 医薬組成物のためのスルホキシイミン置換キナゾリン Expired - Fee Related JP6479854B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14167373 2014-05-07
EP14167373.1 2014-05-07
PCT/EP2015/059453 WO2015169677A1 (en) 2014-05-07 2015-04-30 Sulfoximine substituted quinazolines for pharmaceutical compositions

Publications (3)

Publication Number Publication Date
JP2017514867A JP2017514867A (ja) 2017-06-08
JP2017514867A5 true JP2017514867A5 (enExample) 2018-09-20
JP6479854B2 JP6479854B2 (ja) 2019-03-06

Family

ID=50639371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566786A Expired - Fee Related JP6479854B2 (ja) 2014-05-07 2015-04-30 医薬組成物のためのスルホキシイミン置換キナゾリン

Country Status (7)

Country Link
US (1) US10167296B2 (enExample)
EP (1) EP3140300B1 (enExample)
JP (1) JP6479854B2 (enExample)
AU (1) AU2015257917C1 (enExample)
CA (1) CA2944103A1 (enExample)
ES (1) ES2749186T3 (enExample)
WO (1) WO2015169677A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170066778A1 (en) * 2015-09-04 2017-03-09 Aunova Medchem LLC Solubility for target compounds
WO2017165908A1 (en) * 2016-03-31 2017-10-05 South Australian Health And Medical Research Institute Limited Method of inhibiting high fat diet-related conditions

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
SE0102147D0 (sv) 2001-06-18 2001-06-18 Pharmacia Ab New methods
EP2277552A1 (en) 2001-10-29 2011-01-26 Boehringer Ingelheim International GmbH Mnk kinase proteins and diabetes
GB0315587D0 (en) 2003-07-03 2003-08-13 Univ Dundee Anti-inflammatory assay and compounds
MXPA06011589A (es) 2004-04-08 2006-12-20 Dow Agrosciences Llc Sulfoximinas n-sustituidas insecticidas.
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
CA2655799A1 (en) * 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
WO2007104053A2 (en) 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
CN101466716A (zh) * 2006-04-07 2009-06-24 德维洛根股份公司 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶
WO2007147874A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
CA2687611A1 (en) * 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Novel sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors
UY32072A (es) * 2008-08-26 2010-03-26 Boehringer Ingelheim Int Tienopirimidinas para composiciones farmacéuticas
WO2010117425A1 (en) 2009-03-31 2010-10-14 Biogen Idec Ma Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
TW201141872A (en) * 2010-02-26 2011-12-01 Boehringer Ingelheim Int Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
EA201201192A1 (ru) * 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций
US9170933B2 (en) * 2010-06-28 2015-10-27 International Business Machines Corporation Wear-level of cells/pages/sub-pages/blocks of a memory
AR088082A1 (es) 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
ES2591129T3 (es) 2012-05-21 2016-11-25 Bayer Pharma Aktiengesellschaft Tienopirimidinas
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
CA2885783A1 (en) * 2012-09-26 2014-04-03 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
ES2635262T3 (es) * 2012-11-09 2017-10-03 Evotec International Gmbh Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas
WO2014118226A1 (en) * 2013-02-01 2014-08-07 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
DK3013805T3 (en) * 2013-06-28 2018-04-23 Evotec Int Gmbh Sulfoximine-substituted quinazolines and their use as MNK1 and / or MNK2 kinase inhibitors
JP6457523B2 (ja) * 2013-12-04 2019-01-23 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 医薬組成物のためのスルホキシイミン置換キナゾリン

Similar Documents

Publication Publication Date Title
ES3036123T3 (en) Heterocyclic rip1 kinase inhibitors
JP7145931B2 (ja) 化合物の結晶多形、その製造方法及び用途
CA3150701A1 (en) Alkynyl quinazoline compounds
JP2016121196A5 (enExample)
JP2018515495A5 (enExample)
JP2016512823A5 (enExample)
CN105934432A (zh) 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
MX2015004787A (es) Compuestos antiviricos para el virus sincitial respiratorio.
CA3142069A1 (en) Aurora kinase inhibitor and use thereof
JP2016519165A5 (enExample)
AU2015335783B2 (en) Tricyclic atropisomer compounds
EP3227270A2 (en) Heterocyclic derivatives and use thereof
JP2015508092A5 (enExample)
JP2017527598A5 (enExample)
WO2017084640A1 (zh) 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用
JP2019532067A5 (enExample)
JP2015502371A5 (enExample)
JP2021532107A (ja) ジカチオン化合物及びその製造方法と使用
US20190202826A1 (en) Phosphotidylinositol 3-Kinase Inhibitors
WO2018133875A1 (zh) Jak酶抑制剂及其制备方法和用途
JPWO2009041559A1 (ja) インダゾールアクリル酸アミド化合物
JP2025540714A (ja) Ｌｐａ受容体活性と関連する状態を処置するための化合物および組成物
JP2017514867A5 (enExample)
JP2020517676A5 (enExample)
AU2023225907A1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity